aod9604 phase 2 trial results weight loss kg or percent Orforglipron: The Oral Non-Peptide GLP-1 Agonist AOD-9604 Vial — Lyophilized, HPLC

Rinderknecht E, Humbel RE

The compound also shows no inhibitory activity against nicotinamide phosphoribosyltransferase (NAMPT) or sirtuin 1 (SIRT1), key enzymes in the NAD+ salvage pathway

In 2008, Calzada obtained a TGA classification of AOD-9604 as a supplementary substance in Australia, not as a drug, but as a safe component of food supplements

Sources: Neelakantan et al., Biochem Pharmacol 2018 | Dimet-Wiley et al., Sci Rep 2024 Security Profile & Chemical Identity Molecular specifications and preclinical safety data 5-Amino-1MQ Chemical Identity A small molecule derived from quinolinium salts, developed at the University of Texas (2017) 5-Amino-1MQ Tolerance & Status Safety data from preclinical studies (DIO mouse model) Published Preclinical Data 3 key studies published in Biochemical Pharmacology and Scientific Reports 35% Reduction of white adipose tissue in 11 days (20 mg/kg, 3 times/day) Physical Effects (11 days) + 40 % Improvement of grip strength in aged mice (22-24 months) Strength & Performance (aged mice) microbiome The combination of 5-Amino-1MQ + caloric restriction establishes a distinct gut microbial profile Protocol & Results Important Notice Search Only Not intended for human consumption

Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3